Directorate Change

RNS Number : 9282N

Advanced Oncotherapy PLC

01 November 2016

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Directorate Change

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Lord David Evans has stepped down from the Board with immediate effect. In addition, the board of directors of Advanced Oncotherapy intends to appoint Professor Stephen Myers as member of the Board. A further announcement in relation to the proposed appointment of Professor Stephen Myers will be made in due course.

Professor Steve Myers OBE, was appointed Executive Chairman of Advanced Oncotherapy's fully owned subsidiary ADAM S.A. ("ADAM") a year ago and, since then, has delivered with the ADAM team significant progress in designing and developing the Company's next-generation proton beam cancer therapy technology, the ground-breaking LIGHT system.

Professor Myers was Head of Medical Applications at CERN in Geneva from 2014 until 2016. From 2009-2013, he was the Director of Accelerators and Technology, where he was responsible for the operation and exploitation of the whole CERN accelerator complex, with particular emphasis on the Large Hadron Collider ("LHC") and for the development of the new projects and technologies.

In 2012, he was elected as a Fellow of the Royal Academy of Engineering which honours the UK's most eminent engineers, and is a Fellow of the Institute of Physics, the European Physical Society and International Fellow of the American Physical Society. He is internationally recognised for his engineering contributions and leadership in the development of CERN's particle colliders over the past 40 years, including the Intersecting Storage Ring Accelerator, the Large Electron-Positron collider and the LHC.

Professor Myers has been awarded a number of international prizes including the Duddel Prize & Medal from the Institute of Physics (now re-named the Gabor Medal & Prize) and was awarded an OBE in 2013 for services to science and technology. Professor Myers holds a number of honorary and advisory positions and is Chair of the Advisory Committees of both the John Adams Accelerator Institute in Oxford and the Cockcroft Accelerator Institute and has published over 300 scientific papers.

Commenting, Mike Sinclair, Executive Chairman of Advanced Oncotherapy, said: "We are very pleased with the proposed appointment of Professor Steve Myers to the Board. Since his appointment at ADAM, Professor Steve Myers has provided the Company with invaluable advice and extensive knowledge. We are extremely lucky to have someone of his calibre joining the board of Advanced Oncotherapy. On behalf of the Board, I would like to thank Lord Evans for his hard work and dedication over the years, and wish him every success in the future. David has been involved with the Company since its inception and has made a significant contribution to our development in terms of both his commercial and political prowess, and for which we are very grateful."

Commenting, Prof. Stephen Myers, said: "I am very pleased to be part of Advanced Oncotherapy, both as Executive Chairman of ADAM and in the future as member of the Board of Advanced Oncotherapy. This represents a unique opportunity and I look forward to sharing further my own experience and knowledge of the industry with the company."

Advanced Oncotherapy Plc	www.avoplc.com
Dr Michael Sinclair, Executive Chairman Nicolas Serandour, CEO	Tel: [phone]
Stockdale Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten
	Tel: [phone]
Beaufort Securities (Joint Broker)
Jon Belliss / Elliot Hance
	Tel: [phone]
Walbrook PR (Financial PR & IR)
Paul McManus / Anna Dunphy	Tel: [phone] or [e-mail]
	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

BOAWGGRGUUPQPUG